黑色素瘤治疗研究进展
发布时间：2019-06-10 18:41
【摘要】：黑色素瘤是一种曾经让医生束手无策的恶性肿瘤,既往治疗手段有限,放疗、化疗及传统免疫治疗疗效不佳,患者预后极差。2011年以来,小分子靶向药物(包括BRAF抑制剂Vemurafenib、Dabrafenib,MEK抑制剂Trametinib等药物)相继面世,预示着黑色素瘤内科治疗进入一个新的研究阶段。而免疫靶向治疗(如抗CTLA-4抗体,抗PD-1、PD-L1抗体)在多项临床试验中的成功,更是缔造了肿瘤治疗的新理念。黑色素瘤治疗逐渐摆脱传统抗肿瘤治疗的模式,进入一个崭新的历史阶段,在可预见的将来,新治疗靶点的研发、多种小分子靶向药物、多种免疫靶向药物的联合治疗,以及小分子靶向药物和免疫靶向药物的联合治疗等模式将会是黑色素瘤治疗的主流。本文主要从小分子靶向药物治疗、免疫靶向治疗、化疗3个方面综述黑色素瘤治疗的研究进展。
[Abstract]:Melanoma is a malignant tumor that once left doctors helpless. Previous treatments are limited, radiotherapy, chemotherapy and traditional immunotherapy are not effective, and the prognosis of patients is very poor. Since 2011, small molecule targeting drugs (including BRAF inhibitor Vemurafenib,) Dabrafenib,MEK inhibitor Trametinib and other drugs have been introduced one after another, indicating that the medical treatment of melanoma has entered a new stage of research. The success of immunotargeted therapy (such as anti-CTLA-4 antibody, anti-PD-1,PD-L1 antibody) in many clinical trials has created a new concept of tumor treatment. Melanoma treatment gradually got rid of the traditional anti-tumor treatment model and entered a new historical stage. In the foreseeable future, the research and development of new treatment targets, a variety of small molecule targeted drugs, a variety of immunotargeted drugs combined treatment. And the combination of small molecule targeted drugs and immunotargeted drugs will be the mainstream of melanoma treatment. In this paper, the research progress of melanoma treatment was reviewed in three aspects: small molecular targeted drug therapy, immunotargeted therapy and chemotherapy.
【作者单位】： 北京大学肿瘤医院;北京市肿瘤防治研究所肾癌黑色素瘤内科;恶性肿瘤发病机制及转移研究教育部重点实验室;
【分类号】：R739.5
[Abstract]:Melanoma is a malignant tumor that once left doctors helpless. Previous treatments are limited, radiotherapy, chemotherapy and traditional immunotherapy are not effective, and the prognosis of patients is very poor. Since 2011, small molecule targeting drugs (including BRAF inhibitor Vemurafenib,) Dabrafenib,MEK inhibitor Trametinib and other drugs have been introduced one after another, indicating that the medical treatment of melanoma has entered a new stage of research. The success of immunotargeted therapy (such as anti-CTLA-4 antibody, anti-PD-1,PD-L1 antibody) in many clinical trials has created a new concept of tumor treatment. Melanoma treatment gradually got rid of the traditional anti-tumor treatment model and entered a new historical stage. In the foreseeable future, the research and development of new treatment targets, a variety of small molecule targeted drugs, a variety of immunotargeted drugs combined treatment. And the combination of small molecule targeted drugs and immunotargeted drugs will be the mainstream of melanoma treatment. In this paper, the research progress of melanoma treatment was reviewed in three aspects: small molecular targeted drug therapy, immunotargeted therapy and chemotherapy.
【作者单位】： 北京大学肿瘤医院;北京市肿瘤防治研究所肾癌黑色素瘤内科;恶性肿瘤发病机制及转移研究教育部重点实验室;
【分类号】：R739.5
【共引文献】
相关期刊论文 前9条
1 Meng-Ze Hao;Wen-Ya Zhou;Xiao-Ling Du;Ke-Xin Chen;Guo-Wen Wang;Yun Yang;Ji-Long Yang;;Novel anti-melanoma treatment:focus on immunotherapy[J];Chinese Journal of Cancer;2014年09期
2 敖俊红;杨蓉娅;;转移性黑素瘤的治疗选择[J];实用皮肤病学杂志;2013年04期
3 郑永卿;刘文超;;晚期黑色素瘤的个体化靶向治疗研究进展[J];实用肿瘤杂志;2014年01期
4 田慧;耿傲蕾;邓骥;;联合运用化疗药物、疫苗和单克隆抗体进行抗癌治疗[J];中国药房;2010年38期
5 张艳丽;祝顺琴;刘亚玲;崔红娟;;恶性黑色素瘤内科治疗研究进展[J];肿瘤防治研究;2014年01期
6 袁溪;杜蓉;魏静;魏e，
本文编号：2496652
本文链接：https://www.wllwen.com/yixuelunwen/pifb/2496652.html
最近更新
教材专著
